JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Varney, M. A.
Right arrow Articles by Johnson, E. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Varney, M. A.
Right arrow Articles by Johnson, E. C.

Vol. 290, Issue 1, 170-181, July 1999

SIB-1757 and SIB-1893: Selective, Noncompetitive Antagonists of Metabotropic Glutamate Receptor Type 5

Mark A. Varney, Nicholas D. P. Cosford, Christine Jachec, Sara P. Rao, Aida Sacaan, Fen-Fen Lin, Leo Bleicher, Emily M. Santori, Peter J. Flor, Hans Allgeier, Fabrizio Gasparini, Rainer Kuhn, Stephen D. Hess, Gönül Veliçelebi and Edwin C. Johnson

SIBIA Neurosciences, Inc., La Jolla, California (M.A.V., N.D.P.C., C.J., S.P.R., A.S., F.-F.L., L.B., E.M.S., S.D.H., G.V., E.C.J.); and Novartis Pharma AG, Nervous System, Basel, Switzerland (P.J.F., H.A., F.G., R.K.)

Cell lines expressing the human metabotropic glutamate receptor subtype 5a (hmGluR5a) and hmGluR1b were used as targets in an automated high-throughput screening (HTS) system that measures changes in intracellular Ca2+ ([Ca2+]i) using fluorescence detection. This functional screen was used to identify the mGluR5-selective antagonist, SIB-1757 [6-methyl-2-(phenylazo)-3-pyridinol], which inhibited the glutamate-induced [Ca2+]i responses at hmGluR5 with an IC50 of 0.37 µM compared with an IC50 of >100 µM at hmGluR1. Schild analysis demonstrated a noncompetitive mechanism of inhibition. Pharmacophore mapping was used to identify an additional compound, SIB-1893 [(E)-2-methyl-6-(2-phenylethenyl)pyridine], which was also shown to block glutamate-induced increases in [Ca2+]i at hmGluR5 with an IC50 of 0.29 µM compared with an IC50 of >100 µM at hmGluR1. SIB-1757 and SIB-1893 showed little or no activity when tested for agonist and antagonist activity at the other recombinant human mGluR subtypes, alpha -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, kainate, and N-methyl-D-aspartate receptors. In rat neonatal brain slices, SIB-1757 and SIB-1893 inhibited (S)-3,5-dihydroxyphenylglycine (DHPG)-evoked inositol phosphate accumulation in hippocampus and striatum by 60% to 80%, with a potency similar to that observed on recombinant mGluR5. However, in the cerebellum, a brain region with low mGluR5 expression, SIB-1757 failed to inhibit DHPG-evoked inositol phosphate accumulation. In cultured rat cortical neurons, SIB-1757 and SIB-1893 largely inhibited DHPG-evoked [Ca2+]i signals, revealing a population of neurons that were less sensitive to SIB-1757 and SIB-1893. This is the first description of highly selective, noncompetitive mGluR5 antagonists. These compounds will be useful tools in evaluating the role of mGluR5 in normal physiology and in animal models of disease.

0022-3565/99/2901-0170$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
Y. Chen, C. Goudet, J.-P. Pin, and P. J. Conn
N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) Acts through a Novel Site as a Positive Allosteric Modulator of Group 1 Metabotropic Glutamate Receptors
Mol. Pharmacol., March 1, 2008; 73(3): 909 - 918.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. Suzuki, N. Tsukamoto, H. Fushiki, A. Kawagishi, M. Nakamura, H. Kurihara, M. Mitsuya, M. Ohkubo, and H. Ohta
In Vitro Pharmacological Characterization of Novel Isoxazolopyridone Derivatives as Allosteric Metabotropic Glutamate Receptor 7 Antagonists
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 147 - 156.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Storto, L. Capobianco, G. Battaglia, G. Molinaro, R. Gradini, B. Riozzi, A. Di Mambro, K. J. Mitchell, V. Bruno, M. P. Vairetti, et al.
Insulin Secretion Is Controlled by mGlu5 Metabotropic Glutamate Receptors
Mol. Pharmacol., April 1, 2006; 69(4): 1234 - 1241.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Zhang, A. L. Rodriguez, and P. J. Conn
Allosteric Potentiators of Metabotropic Glutamate Receptor Subtype 5 Have Differential Effects on Different Signaling Pathways in Cortical Astrocytes
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1212 - 1219.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. H. P. Porter, G. Jaeschke, W. Spooren, T. M. Ballard, B. Buttelmann, S. Kolczewski, J.-U. Peters, E. Prinssen, J. Wichmann, E. Vieira, et al.
Fenobam: A Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive mGlu5 Receptor Antagonist with Inverse Agonist Activity
J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 711 - 721.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
G. Battaglia, C. L. Busceti, G. Molinaro, F. Biagioni, M. Storto, F. Fornai, F. Nicoletti, and V. Bruno
Endogenous Activation of mGlu5 Metabotropic Glutamate Receptors Contributes to the Development of Nigro-Striatal Damage Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in Mice
J. Neurosci., January 28, 2004; 24(4): 828 - 835.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
H. Schaffhauser, B. A. Rowe, S. Morales, L. E. Chavez-Noriega, R. Yin, C. Jachec, S. P. Rao, G. Bain, A. B. Pinkerton, J.-M. Vernier, et al.
Pharmacological Characterization and Identification of Amino Acids Involved in the Positive Modulation of Metabotropic Glutamate Receptor Subtype 2
Mol. Pharmacol., October 1, 2003; 64(4): 798 - 810.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. A. O'Brien, W. Lemaire, T.-B. Chen, R. S. L. Chang, M. A. Jacobson, S. N. Ha, C. W. Lindsley, H. J. Schaffhauser, C. Sur, D. J. Pettibone, et al.
A Family of Highly Selective Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5
Mol. Pharmacol., September 1, 2003; 64(3): 731 - 740.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. J. Anderson, S. P. Rao, B. Rowe, D. R. Giracello, G. Holtz, D. F. Chapman, L. Tehrani, M. J. Bradbury, N. D. P. Cosford, and M. A. Varney
[3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine Binding to Metabotropic Glutamate Receptor Subtype 5 in Rodent Brain: In Vitro and in Vivo Characterization
J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1044 - 1051.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
V. Heidinger, P. Manzerra, X. Q. Wang, U. Strasser, S.-P. Yu, D. W. Choi, and M. M. Behrens
Metabotropic Glutamate Receptor 1-Induced Upregulation of NMDA Receptor Current: Mediation through the Pyk2/Src-Family Kinase Pathway in Cortical Neurons
J. Neurosci., July 1, 2002; 22(13): 5452 - 5461.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. Sakai, G. T. Swanson, K. Shimamoto, T. Green, A. Contractor, A. Ghetti, Y. Tamura-Horikawa, C. Oiwa, and H. Kamiya
Pharmacological Properties of the Potent Epileptogenic Amino Acid Dysiherbaine, a Novel Glutamate Receptor Agonist Isolated from the Marine Sponge Dysidea herbacea
J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 650 - 658.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
V. A. Movsesyan, D. M. O'Leary, L. Fan, W. Bao, P. G. M. Mullins, S. M. Knoblach, and A. I. Faden
mGluR5 Antagonists 2-Methyl-6-(phenylethynyl)-pyridine and (E)-2-Methyl-6-(2-phenylethenyl)-pyridine Reduce Traumatic Neuronal Injury In Vitro and In Vivo by Antagonizing N-Methyl-D-aspartate Receptors
J. Pharmacol. Exp. Ther., January 1, 2001; 296(1): 41 - 47.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
A. Pagano, D. Ruegg, S. Litschig, N. Stoehr, C. Stierlin, M. Heinrich, P. Floersheim, L. Prezeau, F. Carroll, J.-P. Pin, et al.
The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors
J. Biol. Chem., October 20, 2000; 275(43): 33750 - 33758.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. A. Jensen, P. O. Sheppard, L. B. Jensen, P. J. O'Hara, and H. Brauner-Osborne
Construction of a High Affinity Zinc Binding Site in the Metabotropic Glutamate Receptor mGluR1. NONCOMPETITIVE ANTAGONISM ORIGINATING FROM THE AMINO-TERMINAL DOMAIN OF A FAMILY C G-PROTEIN-COUPLED RECEPTOR
J. Biol. Chem., March 23, 2001; 276(13): 10110 - 10118.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. A. Jensen, T. A. Spalding, E. S. Burstein, P. O. Sheppard, P. J. O'Hara, M. R. Brann, P. Krogsgaard-Larsen, and H. Brauner-Osborne
Functional Importance of the Ala116-Pro136 Region in the Calcium-sensing Receptor. CONSTITUTIVE ACTIVITY AND INVERSE AGONISM IN A FAMILY C G-PROTEIN-COUPLED RECEPTOR
J. Biol. Chem., September 15, 2000; 275(38): 29547 - 29555.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.